Pharmaceutical aspects of drug eluting stents

Deconinck, Éric; Sohier, J.; Scheerder, Ivan De; Mooter, Guy Van den

doi:10.1002/jps.21356

Cited by 34 publications

(34 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate-controlling system ensures drug retention during stent deployment and modulates drug-elution kinetics. The optimal release profile should be such that the concentration of drug is at any time sufficient to inhibit the proliferation of smooth muscle cells without influencing the reendothelialization process of the endothelial wall (Deconinck et al, 2008). While it is evident that a DES manages to suppress neointimal growth, it can also provoke inflammatory response and local toxicity by interfering with cellular activities.…”

Section: Importance Of Controlled Drug Elution For Desmentioning

confidence: 99%

Mechanism of controlled release kinetics from medical devices

Raval

Parikh

2010

Braz. J. Chem. Eng.

View full text Add to dashboard Cite

-Utilization of biodegradable polymers for controlled drug delivery has gained immense attention in the pharmaceutical and medical device industry to administer various drugs, proteins and other biomolecules both systematically and locally to cure several diseases. The efficacy and toxicity of this local therapeutics depends upon drug release kinetics, which will further decide drug deposition, distribution, and retention at the target site. Drug Eluting Stent (DES) presently possesses clinical importance as an alternative to Coronary Artery Bypass Grafting due to the ease of the procedure and comparable safety and efficacy. Many models have been developed to describe the drug delivery from polymeric carriers based on the different mechanisms which control the release phenomenon from DES. Advanced characterization techniques facilitate an understanding of the complexities behind design and related drug release behavior of drug eluting stents, which aids in the development of improved future drug eluting systems. This review discusses different drug release mechanisms, engineering principles, mathematical models and current trends that are proposed for drug-polymer coated medical devices such as cardiovascular stents and different analytical methods currently utilized to probe diverse characteristics of drug eluting devices.

show abstract

Section: Importance Of Controlled Drug Elution For Desmentioning

confidence: 99%

Mechanism of controlled release kinetics from medical devices

Raval

Parikh

2010

Braz. J. Chem. Eng.

View full text Add to dashboard Cite

show abstract

“…The literature concerning the three cardiovascular implantable devices was reviewed (Andrade et al, 2000;Brasil, 2009a;Deconinck et al, 2008;Emergency…, 2005a, b;França and Pereira, 2008;Instituto…, 2009;Hoffman, 2009;Kalil et al, 2006;Martinelli, 2008;Nelken and Schneider, 2004) as well as the users´ guide and labeling information of the medical devices, available at Anvisa's website (Brasil, 2003) …”

Section: Definition Of the Technical Attributes Of Each Device Groupmentioning

confidence: 99%

Systematization of information for identifying similar cardiovascular implantable devices

2015

View full text Add to dashboard Cite

Introduction: The lack of a terminology to compare medical devices together with the arbitrary and opaque nature of product registration systems are major obstacles to a more informed decision process regarding the use and acquisition of new medical devices. This paper describes the systematization of information to help in the identifi cation of similar cardiovascular implantable devices. Methods: The systematization was developed in four stages: defi nition of the technical attributes of each device group; classifi cation of a sample of devices; implementation of the proposed systematization in Protégé; and evaluation of the application. The systematization dealt with a set of common attributes -indication of use, anatomic location, manufacturer, device model and lifetime; and a set of attributes specifi c for each type of device. Results: The systematization was performed by means of a hierarchy of classes with the respective properties in Protégé, which support three basic functions: data entry, query, and maintenance. 38 queries were designed to allow the identifi cation of similar devices according to their technical characteristics. The users' evaluation showed that the application fulfi lled the requirements to monitor the price of these devices on the market. Conclusions: Protégé was a useful tool for the systematization of cardiovascular implantable devices that can be used for the post-market vigilance of medical device safety. To better fulfi ll this aim, other attributes may be incorporated to better characterize the safety aspects of these devices.

show abstract

“…The mTor inhibitors are cytostatic drugs and show their effects by stopping the cell cycle at G1 phase. Sirolimus acts by binding to FK506 binding protein-12 and inhibits restenosis cascade by blocking inflammation, neointimal hyperplasia, collagen synthesis and migration of smooth muscle cells (24). Zotarolimus and everolimus as well inhibit smooth muscle cell and T cell proliferation by binding to FK506 binding protein-12 (24).…”

Section: Limus Familymentioning

confidence: 99%

“…Sirolimus acts by binding to FK506 binding protein-12 and inhibits restenosis cascade by blocking inflammation, neointimal hyperplasia, collagen synthesis and migration of smooth muscle cells (24). Zotarolimus and everolimus as well inhibit smooth muscle cell and T cell proliferation by binding to FK506 binding protein-12 (24). Novolimus and myolimus are new mTOR inhibitors, which have been also clinically tested (25,26).…”

Section: Limus Familymentioning

confidence: 99%